A plethora of trials have already been devised and are currently in various stages of development and implementation.
However, a systematic review evaluating studies on treatment of PONV stated that there is a discrepancy between the plethora of trials on prevention of PONV and the paucity of trials on the treatment of established symptoms [ 10].
The discrepancy between the plethora of trials on prevention of PONV and the paucity of trials on treatment of established symptoms is due, in part, to the difficulty in performing PONV treatment studies since a large number of patients would be needed to obtain the required target sample size that eventually experience PONV.
For several reasons, however, it is unlikely that randomized controlled trials will be performed that help to fill the gap between the huge knowledge that has accumulated by a plethora of antiemetic trials investigating the prophylaxis and the little knowledge on treatment of established symptoms due to the paucity trials on the treatment of PONV.
The problem is that antibiotic treatment duration studies, especially for cellulitis, are relatively scarce amidst the plethora of clinical trials that usually compare newer to older antibiotics, sometimes with different durations.
The findings from this work have spawned a plethora of clinical trials investigating CDK4/6 inhibitor breast cancer, and support the overall contention that the RB pathway does represent an actionable target in ER-positive breast cancer.
There is a plethora of randomised clinical trials on the prevention of PONV symptoms and a paucity of therapeutic trials, and there may be several reasons for this discrepancy.
For this study we have chosen CIMT because of the advantage of standardization of measurement and the plethora of randomized controlled trials using this surrogate marker [ 21].
Since 2000 a plethora of randomised controlled trials and systematic reviews have examined internet-based interventions for both psychological [ 19, 20] and physical [ 17, 18] health complaints.
In addition to the plethora of current randomised, controlled trials, various nonrandomised clinical trials will explore the potential efficacy and safety of trastuzumab, bevacizumab, sorafenib, and erlotinib in combination with an AI as first-line or second-line therapy, and one trial will test the combination of anastrozole, fulvestrant and gefinitib in the neoadjuvant setting.
A plethora of unsuccessful phase 2 trials of targeted compounds, either alone or combined with chemotherapy, was tested in UC at different clinical stages.
